Lipigon presents Lipisense® at Global CVCT Forum 2023
Lipigon's CEO Stefan K. Nilsson will be taking part in the prestigious Global Cardio Vascular Clinical Trialists (CVCT) Forum 2023. This event will take place from November 30 to December 1 at The National Press Club in Washington DC.
The Global CVCT Forum is an annual gathering of a diverse group of experts who come together to discuss clinical trials in cardiovascular medicine. Participants include researchers, clinicians, industry representatives, patients, regulatory authorities, and investors. The forum offers expert discussions and a unique program focusing on cutting-edge, evidence-based clinical trials in cardiovascular, cardiorenal and cardiometabolic medicine. It serves as an important platform for networking and collaboration in cardiovascular disease research.
Lipigon's CEO Stefan K. Nilsson will participate as a panelist in two sessions on November 30. In the second session, he will also introduce Lipigon and the company's innovative RNA drug, Lipisense®:
- Panel discussion on the topic "Clinical Trials Targeting Lipoprotein(a) and Inflammation for Atherosclerosis Therapy".
- Stefan K. Nilsson presents and participates in a panel discussion on the topic "Triglyceride Rich Lipoproteins Trials".
"Being invited to the CVCT Forum is not only a great honor but also a recognition of the important work we are doing at Lipigon. Our dedication and research into ANGPTL4, as well as the development of Lipisense®, have generated tremendous interest within the medical community. Having the opportunity to share our research with some of the world's foremost experts, pharmaceutical companies, and investors within cardiovascular medicine is both flattering and confirms the interest in our work," says Stefan K. Nilsson, CEO of Lipigon.
Lipisense® is an RNA drug developed to reduce triglyceride levels in patients with severely elevated levels by preventing the production of the ANGPTL4 protein. Recently, Lipigon presented significant data from the Phase I study, showing that Lipisense® reduced the target protein ANGPTL4 in the blood upon repeated dosing in all treatment groups in the MAD (Multiple Ascending Doses) part of the Phase I study.
For more information, please contact:
Stefan K. Nilsson, CEO, Lipigon
Email: [email protected]
Phone: +46 705 78 17 68
Lipigon Pharmaceuticals AB is a clinical-stage pharmaceutical company developing drugs with new, unique mechanisms of action (first-in-class) for diseases caused by disorders in the body's handling of fats. The company's operations are based on over 50 years of lipid research at Umeå University, Sweden. Lipigon's initial focus is on orphan drugs and niche indications, but in the long term, the company has the possibility to target broader indications, such as diabetes and cardiovascular disease. Lipigons pipeline includes four active projects: the RNA drug candidate Lipisense® targeting elevated triglycerides, with Phase II studies planned for Q1 2024, an RNA drug candidate for the treatment of lung damage, a gene therapy treatment for the rare disease lipodystrophy in collaboration with Combigene AB (publ), and a small molecule program for the treatment of dyslipidemia in collaboration with HitGen (Inc). Read more at www.lipigon.se.
The company's share (LPGO) is traded on the Nasdaq First North Growth Market. Certified Adviser is G&W Fondkommission.
Få löpande information från Lipigon via e-post.